Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63187-735

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63187-735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in Duloxetine Delayed-Release 60 mg capsules by Proficient Rx LP. The diagram shows the molecular arrangement of duloxetine with its characteristic bicyclic and thiophene rings and the attached amine hydrochloride group.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: CYM 60 mg BID, CYM 60 mg QD, CYM 20 mg QD, and Placebo, shown with distinct symbols. The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. Vertical dashed lines mark specific improvement thresholds.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph illustrating the percentage of patients improved relative to the percent improvement in pain from baseline. The graph compares three groups: CYM 60 mg twice daily (BID), CYM 60 mg once daily (QD), and placebo, showing trends of patient improvement percentages decreasing as pain improvement percentages increase from above 0 to 100.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows data for placebo patients and for patients taking CYM60/120 mg once daily, with the latter generally demonstrating higher patient improvement percentages across the pain improvement spectrum.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph comparing the percentage of patients improved over various levels of percent pain improvement from baseline (BOCF) between a placebo group and a group receiving 60 mg once daily of Duloxetine Hydrochloride (CYM60 mg). The x-axis shows percent improvement thresholds, while the y-axis indicates the percentage of patients improved. The graph illustrates differences in patient responses between the treatment and placebo groups.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. Two lines compare placebo and CYM60/120 mg once daily treatments, illustrating pain improvement distribution across different thresholds from greater than 0% to 100%.*

FDA Label Image

63187-735-30 (Duloxetine 09)

DULOXETINE DELAYED-RELEASE 60 mg capsule label by Proficient Rx LP. The label indicates it contains delayed release (DR) capsules, quantity 30, with each capsule containing 67.3 mg duloxetine hydrochloride USP equivalent to 60 mg duloxetine. The label includes storage instructions and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.